Lycorine (1,2-didehydrolycorine)

Lycorine is a naturally occurring Amaryllidaceae alkaloid found in plants such as daffodil (Narcissus spp.) and spider lily (Lycoris radiata), characterized by a tetracyclic pyrrolo[3,2,1-ij]quinoline core structure. Its primary mechanisms involve inhibition of protein synthesis, suppression of JAK2/STAT3 signaling cascades, and induction of apoptosis in cancer cell lines.

Origin & History

Lycorine is a phenanthridine alkaloid primarily isolated from plants in the Amaryllidaceae family, including species of Lycoris, Narcissus, and Galanthus. It is extracted from bulbs or leaves through standard alkaloid isolation methods involving solvent extraction and chromatography.

Historical & Cultural Context

The research sources do not provide information on traditional medicinal uses of lycorine. It is primarily highlighted as a natural lead compound for anticancer drug discovery from Amaryllidaceae plants.

Health Benefits

• May reduce tumor growth and infiltration in leukemia models (preliminary evidence from mouse studies)
• Potentially inhibits esophageal cancer cell proliferation by targeting TRIM22 and JAK2/STAT3 pathways (in vitro and animal studies)
• Shows anti-metastatic activity through STAT3 suppression and reversal of epithelial-mesenchymal transition (preclinical prostate cancer models)
• Demonstrates anti-angiogenic properties through PDGFRα docking (in vitro HUVEC studies)
• Induces cell cycle arrest and apoptosis in multiple cancer cell lines (preliminary in vitro evidence)

How It Works

Lycorine inhibits eukaryotic protein synthesis by interfering with the elongation step of translation at the ribosomal level, reducing proliferative capacity in rapidly dividing cells. It suppresses the JAK2/STAT3 signaling axis by downregulating phosphorylation of STAT3 at Tyr705, thereby reducing transcription of pro-survival genes such as Bcl-2, Mcl-1, and cyclin D1. Additionally, lycorine targets TRIM22, an E3 ubiquitin ligase, to modulate downstream oncogenic pathways and has been shown to activate caspase-3 and caspase-9 to trigger mitochondria-mediated apoptosis.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted with lycorine. All available evidence comes from preclinical in vitro studies and animal models, including SCID mouse xenograft studies showing reduced leukemia cell infiltration and extended survival at 5-10 mg/kg/day doses.

Clinical Summary

The majority of evidence supporting lycorine's bioactivity comes from in vitro cell-line studies and murine xenograft models rather than human clinical trials. In leukemia mouse models, lycorine administration reduced tumor burden and inhibited cancer cell infiltration into tissues, though specific quantified outcomes vary by study and dosing protocol. In esophageal cancer in vitro studies, lycorine suppressed cell proliferation and migration at micromolar concentrations (approximately 1–10 µM) by targeting the TRIM22/JAK2/STAT3 pathway. No peer-reviewed human clinical trials have been completed to date, meaning efficacy and safe dosing in humans remain unestablished.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"lycorine": "Present in trace amounts, specific concentration not well-documented"}, "bioavailability_notes": "Lycorine is primarily studied for its pharmacological effects rather than nutritional value. Its bioavailability and metabolism in humans are not well-characterized."}

Preparation & Dosage

No human dosage data available. Animal studies used 5-10 mg/kg/day intraperitoneally for leukemia models and 5-15 mg/kg/day for other tumor models. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, EGCG, Quercetin, Resveratrol, Berberine

Safety & Interactions

Lycorine has a narrow therapeutic window and exhibits cytotoxicity at higher concentrations in both cancerous and normal cell lines, raising concerns about systemic toxicity in human use. In animal studies, doses exceeding established thresholds have been associated with gastrointestinal distress, emesis, and potential hepatotoxicity, consistent with the broader toxic profile of Amaryllidaceae alkaloids. Lycorine may interact with drugs metabolized via CYP450 enzymes and could theoretically potentiate or antagonize immunosuppressive or chemotherapeutic agents, though direct interaction data in humans are lacking. It is considered unsafe during pregnancy due to its cytotoxic and potential teratogenic properties, and no safe or standardized supplemental dose has been established for human consumption.